About InorbitTX

Inorbit Therapeutics AB

Inorbit Therapeutics AB (InOrbitTX) was founded in 2015. It is a privately owned virtual Drug Discovery and Development company based in the BioVentureHub in Mölndal, near Gothenburg, Sweden. We focus our small molecule drug discovery and development expertise on areas with a high unmet medical need and an excellent market perspective with a special interest for Non Alcoholic Steato Hepatitis (NASH). InOrbitTX applies a unique groundbreaking chemotype to generate its potential new drugs. This chemotype is specifically designed to mitigate the risk for Drug Induced Liver Injury (DILI), a major cause for drug failure in late stages of development and even after approval and marketing. Its current lead compound, the Farnesoid X Receptor (FXR) agonist IOT022, aimed for the treatment of NASH, shows excellent efficacy in a sub-chronic in vivo models with an excellent safety margin. It is currently in pre.clinical development preparing for IND submission. Our second project, the KetoHexoKinase project is in late Candidate Drug nomination phase.

Our leaders have long and successful track records in drug discovery and Development.

Our CEO, Dr. Bert Benthem, born 1962

has held senior positions in the Drug Discovery and Development area with Piramal Healthcare, AstraZeneca, 7TM Pharma and NovoNordisk,
has brought several discovery programs to the clinic,
has a pertinent academic background holding an MSc in Biology and a PhD in Medicine, with specialty in Medical Physiology, both from the University of Groningen, The Netherlands,
has focused his research on metabolic diseases, including NAFLD / NASH, and
has published about 40 scientific papers in peer reviewed journals.

Our CSO, Dr. Robert Judkins, born 1972

has been team leader in the Medicinal Chemistry department with AstraZeneca,
has 20 years of experience in small molecule drug discovery with AZ, Millennium Pharmaceutical, Cambridge Discovery Chemistry and Roche, and
has a proven track record of medicinal chemistry in drug discovery and patent strategy.

Our Head of Drug Development, Dr. Kicki Johansson

holds over 25 years experience in the pharmaceutical industry,
has been directly responsible for strategy and development of nearly 50 drug development projects up to Phase II in a number of different therapeutic areas, and
holds an M.Sc. degree in Pharmacy from Uppsala University and a PhD degree from the University of Gothenburg

Leadership is supported by the Board of Directors:

Wim Mol, Phd, Chair. Wim carries over 20 years of international experience in general management, commercial and R&D positions in the pharmaceutical industry, with, among others, Organon, Schering Plough and Merck. Wim recently retired as CEO at Immunovo BV, a privately held company based in Den Bosch, The Netherlands.

Louise Warme, MD, member. Louise is investment manager at ALMI Invest, Sweden’s most active venture capitalist investing in start-ups. Louise brings a broad experience from (pre-)clinical research, med-tech, and the investment milieu.

Johannes Bruski, PhD, member. Johannes is partner in the law firm Bruski Smeets & Lange. He has extensive know-how and many years of experience in advising on numerous large-volume transactions in the areas of M&A, joint ventures, private equity, and venture capital. He has worked on many private and public mergers, acquisitions and joint ventures, both for strategic and for venture capital/private equity investors, and on other corporate and structured finance transactions.

Göran Gannedahl, MD, member. Göran has a long experience from the medical and pharmaceutical industry within the functions medical affairs, clinical research and business development. He is a medical doctor from Karolinska Institute, has a Ph.D. in Medicine from Uppsala University and has held positions as Global Head of Science Operations at Novartis, VP of R&D in Medical Affairs at Pronova Biopharma, and Executive Global Medical Affairs Leader at AstraZeneca.

Hans-Peter Ostler, member. Hans-Peter has over 20 years experience in investment banking, private banking and asset management. He gained leadership experience with Swedbank Markets, UBS AG, Danske bank and Söderberg&Partners. Hans-Peter has engaged as board member in Swedish and International companies in the areas of Finance Life Science in, among others, Ancoria Insurance Public Ltd and Irlab Therapuetics Ab.

Robert Judkins, PhD, member, see above

Bert Benthem, PhD, member, see above